key: cord-0837025-r2wswgop
authors: Muggeo, Anaëlle; Alauzet, Corentine; Hartard, Cédric; Goury, Antoine; Schvoerer, Evelyne; Andreoletti, Laurent; Guillard, Thomas
title: Co-detection of SARS-CoV-2 and other respiratory pathogens: Lessons from the field to face the second wave
date: 2020-10-15
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104658
sha: bbb22872c22187cf89bc7a1078fe00c625f224d4
doc_id: 837025
cord_uid: r2wswgop

nan

 In hospitalized SARS-CoV-2 patients, respiratory co-infections were rare.  Metapneumovirus was the most common co-infecting pathogen in SARS-CoV-2 patients.  Outside the flu season, documentation of co-infections may provide limited benefit.

Dear Sir,

The first wave of COVID-19 has already infected more than 31 million patients ( propose screening strategies to face a second wave [2] . (Table 1) .

Among the 232 patients, 141 (60.8%) were positive for SARS-CoV-2 and 20 (8.6%) for one or more other pathogens (Table 1) [7] . Interestingly, it has been recently proposed that the low rate of co-infection might stem from the clearance of the SARS-CoV-2 by other respiratory viruses given its lower growth rate [8] . In our non-SARS-CoV-2 infected patients, the high rate of Rhinovirus/Enterovirus and other Coronaviridae may be due to the type I interferon-based competitive inhibition between RNA viruses [9] . A recent study has reported that Metapneumovirus accounts for 3% of patients hospitalized for community-acquired Influenza-like illness during winter in France and affects mainly the elderly and patients with chronic conditions [10] . This could explain that we found Metapneumovirus as the most common co-infecting pathogen in SARS-CoV-2 patients since we focused on hospitalized patients.

Our study has geographical (the north-east of France) and temporal (no overlap with peak flu season) limitations. However, our findings suggest that if SARS-CoV-2 resurges before the flu season, documentation of co-infections may provide limited benefit and could J o u r n a l P r e -p r o o f be proposed as a second-line screening. It is noteworthy that for immunocompromised patients, first-line testing should target several respiratory viruses given that potentially beneficial treatments exist for RSV, Influenza and Parainfluenza virus (e.g. ribavirin, intravenous immunoglobulin, or oseltamivir) [11] [12] .

Despite that flu vaccination has to be promoted in the coming winter, a second wave has to be considered during the flu season. Thereby, it would impose co-screening of Influenza A/B. Although extended multiplex panels that include SARS-CoV-2 are now available (i.e. Biofire respiratory panel RP2.1), endorsing such a strategy may avoid clinical laboratories to be strained either because having no access to expensive tests or facing supply chain difficulties (Figure 1 ).

None to declare 

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Centers for Diseases Control and Prevention. COVID View Weekly Summary

Co-infection in SARS-CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus?

Codetection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia

Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps

SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial?

Mechanisms Controlling Virulence Thresholds of Mixed Viral Populations

Characteristics of human metapneumovirus infection in adults hospitalized for community-acquired influenza-like illness in France, 2012-2018: a retrospective observational study

ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus

Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's Diagnostics Committee